Combined effects of alltransretinoic acid and trichostatin a on the induction of differentiation of thyroid carcinoma cells

Chinese Journal of Cancer

Volumn 29, Issue 4, 2010, Pages 379-384

  Yuan, Geng Biao ^a   Kuang, An Ren ^b   Fan, Qun ^a   Yu, Li Bo ^a   Mi, Yan Xia ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

All trans retinoic acid (RA); Differentiated thyroid carcinoma(DTC); Trichostain A (TSA)

Indexed keywords

RETINOIC ACID; THYROGLOBULIN; TRICHOSTATIN A; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONFORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MONOTHERAPY; SURVIVAL RATE; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; DOSE RESPONSE; PATHOLOGY; SECRETION; THYROID TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; THYROGLOBULIN; THYROID NEOPLASMS; TRETINOIN;

EID: 79955801797     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10589     Document Type: Article

References (19)

1. Mazzaferri EL, Massoll N. Management of papillary and follicular thyroid cancer: new paradigms using recombinant human thyrotropin [J].Endocr Relat Cancer,2002,9(4):227-247.
2. Schlumberger M. Papillary and follicular thyroid carcinoma [J]. N Engl J Med,1998,338(5):297-306.
3. Goretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid carcinoma[J]. Br J Surg,1993,80(8):1009-1012.
4. Haugen BR. Management of patient with progressive radioiodine non-responsive disease[J]. Semin Surg Oncol,1999,16(1):34-41.
5. Piekarz RL, Sackett DL, Bates SE. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy[J]. Cancer,2007, 13 (1): 30-39.
6. Nolan L, Johnson PW, Ganesan A, et al. Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? [J]. British Journal of Cancer,2008,99:689-694.
7. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiated therapy for acute promyelocytic leukemia I clinical results [J]. Blood, 1990,76(9):1704-1709.
8. Grünwald F, Menzel C, Bender H, et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer [J]. J Nucl Med,1998,39:1903-1906.
9. Simon D, Kohrle C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer:final results of a pilot study[J]. Eur J Nucl Med Mol Imaging,2002,29:775-782.
10. Short S C, Suovuori A, Cook G, et al. A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer[J]. Clin Oncol,2004,16:569-574.
11. Naiyer A. John L. Marshall, William Dahut, et al. A Phase I Study of LGD1069 in Adults with Advanced Cancer [J]. Clinical Cancer Research, 1999, 1658(5):1658-1664.
12. Yuan GB, Kuang AR, Fan Q, et al. Investigation of retinoic acid in dedifferentied thyroid carcinoma induction [J]. Chin J Metab.2008, 24 (3): 295-296. [in Chinese]
13. Schreck R, Schnieders F, Schmutzler C, et al. Retinoids stimulate type I iodothyronine 5'-de iodinase activity in human follicular thyroid carcinoma cell lines[J]. J Clin Endocrinol Metab,1994,79(3):791-798.
14. Kurebayashi J, Tanaka K, Otsuki T, et al. All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1 [J]. J Clin Endocrinol Metab,2000,85(8):2889-2896.
15. Van Herle AJ, Agatep ML, Padua DN 3rd, et al. Effects of 13-cis-retinoic acid on growth and differentiation of human follicular carcinoma cells in vitro[J]. J Clin Endocrinol Metab,1990,71(3):755-763.
16. Greenberg VL, Williams JM, Cogswell JP, et al. Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells[J]. Thyroid,2001,11(4):315-325.
17. Chen WK, Chen Y, Gu JX, et al. Effect 0f Trichostatin A on Histone Acetylation Level and Apoptosis in HL-60 Cells [J]. Journal of Experimental Hematology 2004, 12(3):324-328 [in Chinese]
18. Bruel A, Benoit G, De My D, et al. Distinct apoptotic responses in maturation sensitive and resistant t (15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and Bcl-2 expression[J]. Leukemia.,1995,9(7):1173-1184.
19. Kitazono M, Robey R, Zhan Z, et al. Low concentration of the histone deacetylase inhibitor depsipetide (FR901228) increase expression of the Na + /I-symporter and iodine accumulation in pooly differentiated thyroid carcinoma cells[J]. J Clin Endocrinol Metab,2001,86(7):3430-3435.